354 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (90)
- Autoimmune Disorders (1)
- Blood Disorders (4)
- Bone & Muscle (1)
- Cancer (23)
- COVID-19 (Coronavirus) (4)
- (-) Diabetes (2)
- Endocrine & Metabolic Disease (3)
- Healthy Volunteers (10)
- Heart Disease (17)
- Kidney Disease (1)
- Liver Disease (1)
- Lung Disease (2)
- Neurological Disorders (3)
- Nutrition (1)
- Obesity (2)
- Obstetrics & Gynecology (3)
- Pediatrics (7)
- Surgery (2)
- Transplant (3)
Displaying 1 - 4 of 4
Condition: Diabetes
Investigator: Jacqueline Lonier, MD
Status: Currently Recruiting
In PRECIDENTD, we hope to learn which diabetes medications work best to reduce the risk of heart and kidney disease in people with type 2 diabetes. People with type 2 diabetes are twice as likely to have heart disease or a stroke compared to someone who does not have diabetes, and they are likely to have heart disease or stroke at a younger age. People with…
Condition: Diabetes
Investigator: Joshua Cook, MD, PhD
Status: Currently Recruiting
We are conducting a research study on the effect of high insulin levels on the buildup of excessive liver fat ("fatty liver disease") in people at risk for type 2 diabetes. We are seeking adult volunteers, aged 18-70, who are overweight or obese with a body mass index of 27-50, and have been diagnosed with, or are at risk for…
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
XMT-1536 (upifitamab rilsodotin) is a targeted therapy, which means that it is directed specifically at a tumor. It is a type of antibody-drug conjugate; this means it has 2 parts that are joined together into one drug. The first part is an antibody that binds to NaPi2b (sodium-dependent phosphate transporter), a protein on the surface of the cells of your…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE